Women's Fem Dophilus
This product has been discontinued. Label data shown is from the last available version.
Product Information
- Brand
- Jarrow Formulas
- Form
- Capsule
- Servings Per Container
- 30
- UPC
- 7 90011 03005 8
- Product Type
- Non-Nutrient/Non-Botanical
- DSLD Entry Date
- 2020-01-25
Target Groups
Label Statements
Suggested/Recommended/Usage/Directions
Usage: For maintenance, take 1 capsule orally per day, preferably with a meal and a glass of water, and increase to 2 capsules per day as needed or take as directed by your qualified healthcare professional.
Brand IP Statement(s) re: (c), (TM), (SM)
Under license from Chr. Hansen A/S and protected by Chr. Hansen A/S patents of the WO 00/35465 patent family, and others.
Precautions re: Children
Keep out of the reach of children.
Storage
Keep refrigerated.
Formulation re: Does NOT Contain
Free of major allergens.
Formulation re: Vegetarian/Vegan
Suitable for vegetarians/vegans.
FDA Disclaimer Statement
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
General Statements: All Other Content
Made in Denmark by Chr. Hansen A/S
Brand IP Statement(s) re: (c), (TM), (SM)
2019 Jarrow Formulas
Formulation re: Other
Vaginal/Urinary Tract Health
General Statements: All Other Content
Now in veggie cap!
FDA Statement of Identity
Oral Probiotic Supplement
Formulation re: Does NOT Contain
No wheat, gluten, soybeans, dairy, egg, fish/shellfish, or peanuts/tree nuts.
General Statements: All Other Content
Strains matter Jarrow Formulas Probiotics contain clinically documented strains
Formula re: Contains
GR-1/RC-14 and Vaginal Flora (also called microbiota)
General Statements: All Other Content
In one of the randomized clinical trials, 75% of women in the GR-1/RC-14 probiotic group experienced significant improvement in vaginal flora composition, while only 34% of women in the placebo (non-probiotic) group experienced similar improvement. GR-1/RC-14 75% Control Group 34% Martinez, et al. Can J Microbiol 2009;55:133-138 25+ years of GR-1/RC-14 Research/Clinical studies 1988 First research on GR-1/RC-14 strains begin 27 Clinical studies published between 2001 and 2014 Fem-Dophilus introduced (2006)
Precautions re: Pregnant or Nursing or Prescription Medications
If your healthcare professional recommends taking this product in conjunction with antibiotics, take at least 1-2 hours after taking the medication.
Formula re: Contains
Fem-Dophilus contains two patented and clinically documented probiotic strains, Lactobacillus rhamnosis, GR-1 and Lactobacillus reuteri, RC-14, discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech. Over 25 years of research supports the oral use of GR-1 and RC-14 to colonize and promote vaginal and urinary tract health.
Formulation re: Other
A special manufacturing process protects the probiotic strains in Fem-Dophilus from stomach acid and enhances probiotic bacterial survival to the lower intestine.
General Statements: All Other Content
25+ years of research/clinical studies
Brand IP Statement(s) re: (c), (TM), (SM)
2018 Jarrow Formulas
Formula re: Contains
Patented strains Lactobacillus rhamnosus, GR-1 and Lactobacillus reuteri, RC-14
Brand IP Statement(s) re: (c), (TM), (SM)
RC-14 and GR-1 are registered trademarks of Chr. Hansen A/S.
Formulation re: Does NOT Contain
Gluten-free
Formulation re: Vegetarian/Vegan
Vegan
Seals/Symbols
Vegan V Veggie Caps V
General Statements: All Other Content
10518FEM PROD # 103005
Supplement Facts Panel
* Percent Daily Values are based on a 2,000 calorie diet.
† Daily Value not established.